This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Abbott Announces Three-Year Long-Term Data Evaluating Efficacy With HUMIRA® (Adalimumab) For Patients With Moderately To Severely Active Ulcerative Colitis

Stocks in this article: ABT

ABBOTT PARK, Ill., Oct. 22, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA® (adalimumab) ULTRA 1 and ULTRA 2 studies.  Adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to certain other medications and were treated with HUMIRA were evaluated for symptom improvement for up to three years.  In this long-term analysis, ulcerative colitis activity was assessed using the Partial Mayo score, which does not include endoscopic findings.  Results showed:

  • A reduction in observed mean Partial Mayo score (a measure of disease activity that ranges from 0 to 9) from 5.9 at the time of first dose of HUMIRA to 1.4 at week 172 of HUMIRA therapy.
  • A 55.3 percent remission rate, per Partial Mayo score at week 60 of the extension study (reflecting 112 weeks from lead-in study baseline), as assessed in the intent-to-treat patients who enrolled in the open-label study extension.

The data were presented this week at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas, Nevada, and the United European Gastroenterology Week (UEGW) Annual Meeting in Amsterdam, The Netherlands.

"We know ulcerative colitis can be a long-term, disruptive and difficult-to-treat disease," said lead investigator Jean-Frederic Colombel, M.D., professor of gastroenterology and hepatogastroenterology, director of the Department of Hepatogastroenterology, Hopital Huriez, Lille, France.  "These results provide valuable information and insight to further study the long-term use of adalimumab in the treatment of ulcerative colitis."

UC is an inflammatory bowel disease marked by ulcers in the colon and may lead to life-threatening complications.  It is estimated that 25 percent of patients with UC may undergo surgical removal of the colon during their lifetimes, leaving patients with a permanent colostomy or ileal pouch.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,358.21 +162.79 0.95%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,621.3810 +55.2430 1.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs